STERIS plc $STE Shares Bought by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. increased its position in STERIS plc (NYSE:STE) by 688.7% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 44,712 shares of the medical equipment provider’s stock after purchasing an additional 39,043 shares during the period. Dana Investment Advisors Inc.’s holdings in STERIS were worth $11,063,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mediolanum International Funds Ltd lifted its holdings in shares of STERIS by 9.0% in the 2nd quarter. Mediolanum International Funds Ltd now owns 62,327 shares of the medical equipment provider’s stock worth $14,883,000 after purchasing an additional 5,156 shares during the last quarter. Entropy Technologies LP grew its stake in STERIS by 282.2% during the 2nd quarter. Entropy Technologies LP now owns 9,099 shares of the medical equipment provider’s stock worth $2,186,000 after buying an additional 6,718 shares during the last quarter. Vanguard Group Inc. increased its position in STERIS by 1.7% in the second quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock worth $2,921,827,000 after buying an additional 205,276 shares during the period. Asset Management One Co. Ltd. lifted its stake in STERIS by 5.4% in the third quarter. Asset Management One Co. Ltd. now owns 98,487 shares of the medical equipment provider’s stock valued at $24,366,000 after buying an additional 5,072 shares during the last quarter. Finally, Cerity Partners LLC lifted its stake in STERIS by 28.8% in the third quarter. Cerity Partners LLC now owns 96,853 shares of the medical equipment provider’s stock valued at $23,966,000 after buying an additional 21,656 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on STE shares. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $275.20.

STERIS Price Performance

Shares of STERIS stock opened at $246.97 on Tuesday. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. The company’s 50-day moving average price is $255.96 and its two-hundred day moving average price is $251.56. STERIS plc has a 52 week low of $204.90 and a 52 week high of $269.44. The stock has a market cap of $24.22 billion, a PE ratio of 34.45 and a beta of 1.03.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting the consensus estimate of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same quarter last year, the business posted $2.32 earnings per share. The business’s revenue was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, sell-side analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be given a $0.63 dividend. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 annualized dividend and a yield of 1.0%. STERIS’s payout ratio is 35.15%.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.